BridgeBio Pharma Correlations
| BBIO Stock | USD 23.42 0.18 0.77% |
The current 90-days correlation between BridgeBio Pharma and Scpharmaceuticals is 0.27 (i.e., Modest diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BridgeBio Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BridgeBio Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
BridgeBio Pharma Correlation With Market
Modest diversification
The correlation between BridgeBio Pharma and DJI is 0.21 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding BridgeBio Pharma and DJI in the same portfolio, assuming nothing else is changed.
BridgeBio |
Moving together with BridgeBio Stock
Moving against BridgeBio Stock
| 0.48 | KZR | Kezar Life Sciences | PairCorr |
| 0.7 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
| 0.64 | CVX | Chevron Corp Fiscal Year End 7th of February 2025 | PairCorr |
| 0.63 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.62 | HD | Home Depot | PairCorr |
| 0.6 | INTC | Intel Fiscal Year End 23rd of January 2025 | PairCorr |
| 0.59 | HPQ | HP Inc | PairCorr |
| 0.45 | T | ATT Inc Aggressive Push | PairCorr |
| 0.44 | BAC | Bank of America Fiscal Year End 10th of January 2025 | PairCorr |
| 0.42 | GE | GE Aerospace Fiscal Year End 28th of January 2025 | PairCorr |
| 0.4 | VFS | VinFast Auto Earnings Call This Week | PairCorr |
| 0.39 | JPM | JPMorgan Chase Fiscal Year End 10th of January 2025 | PairCorr |
| 0.38 | KB | KB Financial Group | PairCorr |
| 0.33 | DD | Dupont De Nemours Fiscal Year End 4th of February 2025 | PairCorr |
Related Correlations Analysis
| -0.01 | 0.87 | -0.52 | 0.83 | -0.66 | ELYM | ||
| -0.01 | -0.17 | 0.1 | 0.11 | 0.01 | HCWB | ||
| 0.87 | -0.17 | -0.52 | 0.72 | -0.57 | SCPH | ||
| -0.52 | 0.1 | -0.52 | -0.42 | 0.49 | MIST | ||
| 0.83 | 0.11 | 0.72 | -0.42 | -0.6 | MCRB | ||
| -0.66 | 0.01 | -0.57 | 0.49 | -0.6 | LUMO | ||
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between BridgeBio Stock performing well and BridgeBio Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze BridgeBio Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| ELYM | 3.92 | (0.95) | 0.00 | (5.36) | 0.00 | 6.21 | 34.87 | |||
| HCWB | 13.22 | 4.45 | 0.42 | (1.48) | 7.39 | 22.00 | 352.85 | |||
| SCPH | 2.68 | (0.82) | 0.00 | (0.32) | 0.00 | 4.30 | 20.70 | |||
| MIST | 1.92 | 0.21 | 0.13 | 0.25 | 1.60 | 7.19 | 18.66 | |||
| MCRB | 4.68 | 0.01 | (0.02) | 0.25 | 5.68 | 10.00 | 28.84 | |||
| LUMO | 2.77 | 0.61 | 0.15 | (3.14) | 2.60 | 6.35 | 26.13 |
BridgeBio Pharma Corporate Management
| Neil Kumar | President, CoFounder | Profile | |
| MBA CPC | Chief Officer | Profile | |
| Eli Wallace | Chief Oncology | Profile | |
| Frank McCormick | CoFounder Oncology | Profile | |
| Thomas Trimarchi | Chief Officer | Profile |